IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Lonza to Supply Stem Cell Therapy Drug to Maryland Biotech Firm

11:27 AM MDT | July 14, 2008 | Alex Scott

Lonza says it has secured a deal with biotech firm Osiris Therapeutics (Columbia, MD) to manufacture what it says could be the world’s first stem cell drug. The agreement calls for Lonza to manufacture Osiris’s Prochymal stem cell therapy, which is being evaluated in phase III clinical trials for three medical applications including Crohn’s disease. Lonza says it will invest “millions of dollars” to build a Prochymal facility at its Walkersville, MD site. Financial terms were not disclosed. von Hippel: A focus on profitable products...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa